1. ScholarBank@NUS

Lingzhi Wang

rp05443

Collaboration Map View Statistics Email Alert RSS Feed

Profile

Full Name
Lingzhi Wang
Variants
Wang Lingzhi
Wang, L.Z.
Wang, L.-Z.
Wang, L.
 
Main Affiliation
 
Faculty
 
Email
csiwl@nus.edu.sg
 
Other emails
 

Publications

Refined By:
Date Issued:  [2000 TO 2021]
Policy:  Open
Author:  Yong, W.P

Results 1-8 of 8 (Search time: 0.01 seconds).

Issue DateTitleAuthor(s)
12020A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumoursAng, Y.L.E.; Ho, G.F.; Soo, R.A. ; Sundar, R. ; Tan, S.H.; Yong, W.P. ; Ow, S.G.W. ; Lim, J.S.J. ; Chong, W.Q.; Soe, P.P.; Tai, B.C. ; Wang, L. ; Goh, B.C. ; Lee, S.-C. 
22018A review on liquid chromatography-tandem mass spectrometry methods for rapid quantification of oncology drugsWong, A.L.-A ; Xiang, X; Ong, P.S ; Mitchell, E.Q.Y; Syn, N; Wee, I; Kumar, A.P ; Yong, W.P ; Sethi, G ; Goh, B.C ; Ho, P.C.-L ; Wang, L 
32018A sensitive liquid chromatography-tandem mass spectrometry method for the determination of nimbolide in mouse serum: Application to a preclinical pharmacokinetics studyWang, L ; Khoa Phan, D.-D; Syn, N; Xiang, X; Song, H; Thuya, W.L ; Yang, S ; Wong, A.L.-A ; Kumar, A.P ; Yong, W.P ; Sethi, G ; Ho, P.C.-L ; Goh, B.C 
42018Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressorSubhash, V.V; Yeo, M.S; Wang, L ; Tan, S.H; Wong, F.Y; Thuya, W.L ; Tan, W.L; Peethala, P.C ; Soe, M.Y; Tan, D.S.P; Padmanabhan, N ; Baloglu, E; Shacham, S; Tan, P ; Koeffler, H.P ; Yong, W.P 
52016Anticancer properties of nimbolide and pharmacokinetic considerations to accelerate its developmentWang, L ; Khoa Phan, D.D; Zhang, J; Ong, P.-S ; Thuya, W.L ; Soo, R.A ; Wong, A.L.-A ; Yong, W.P ; Lee, S.C ; Ho, P.C.-L ; Sethi, G ; Goh, B.C 
64-Dec-2012Combination Therapy with Gossypol Reveals Synergism against Gemcitabine Resistance in Cancer Cells with High BCL-2 ExpressionWong, F.Y.; Liem, N.; Xie, C.; Yan, F.L.; Wong, W.C.; Wang, L. ; Yong, W.-P. 
72017Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1Wang, L ; Chan, C.E.L; Wong, A.L.-A ; Wong, F.C; Lim, S.W ; Chinnathambi, A; Alharbi, S.A; Lee, L.S.-U ; Soo, R ; Yong, W.P ; Lee, S.C ; Ho, P.C.-L ; Sethi, G ; Goh, B.C 
82019PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoproteinThura M.; Al-Aidaroos A.Q.; Gupta A. ; Chee C.E. ; Lee S.C. ; Hui K.M. ; Li J.; Guan Y.K. ; Yong W.P. ; So J. ; Chng W.J. ; Ng C.H. ; Zhou J. ; Wang L.Z. ; Yuen J.S.P. ; Ho H.S.S. ; Yi S.M.; Chiong E. ; Choo S.P. ; Ngeow J. ; Ng M.C.H. ; Chua C. ; Yeo E.S.A. ; Tan I.B.H. ; Sng J.X.E.; Tan N.Y.Z.; Thiery J.P. ; Goh B.C. ; Zeng Q.